Premium
In vivo Inhibition of Human Platelet Function by VK 744
Author(s) -
SIXMA JAN J.,
TRIESCHNIGG ANNEMIEKE M. C.,
GRAAF SYTSKE,
BOUMA BONNO N.
Publication year - 1972
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1972.tb00935.x
Subject(s) - in vivo , platelet , in vitro , dipyridamole , pharmacology , platelet aggregation , chemistry , function (biology) , medicine , biology , biochemistry , microbiology and biotechnology
VK 744 — a dipyridamole analogue — is an inhibitor of primary aggregation of platelets in vitro. In this paper we describe the in vivo effects in human male volunteers. A dose of 1500 mg VK 744 prolonged the kaolin‐stypven time and inhibited ADP aggregation. Administration of 500 mg three times daily during 48 hrs in a paired coded investigation produced a slightly significant prolongation of the kaolin‐stypven time. Side effects prevented continuation of the trial. The inhibition by indomethacin was not enhanced by combination with VK 744.